Skip to content

Efficacy of Unani eye drops in the Management of Dry eyes syndrome in computer professionals

A Randomized standard controlled pilot study to evaluate the efficacy of Qatur i Chashm (Unani eye drops) in the Management of Digital eye strain in computer professionals - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/02/104016
Enrollment
10
Registered
2026-02-16
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H578- Other specified disorders of eye and adnexa

Interventions

Intervention1: Qutur (eye drops): A classical unani formulation containing Anzarut(Astragalus sarcocolla Dymock),Jau muqashshar (Hordeum vulgare L.),Behidana (Cydonia oblonga Mill. two drops will be

Sponsors

Central Council for Research in Unani Medicine CCRUM
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patients between 18 to 40 years of age with an average computer use of more than or equal to 3 h at a stretch per day or more than or equal to 15 h a week for at least 3 months with complaint of dry eyes. 2)Patients having any of the ocular symptoms (blurring of vision, headache, dry eyes, redness of eyes or eye strain) will be considered to have DES. 3)Patients willing to sign the written informed consent.

Exclusion criteria

Exclusion criteria: 1)A history of active ocular infection or allergy, ocular surgery within the last 12 months. 2)History of any refractive error, recurrent herpetic keratitis, contact lens use, and systemic drugs (such as diuretics antidepressants anxiolytics and antihypertensive) will be excluded from the study. 3)Patients with cardiac diseases and chronic renal failure. 4)Pregnant and lactating mothers. 5)Patients who fail to follow up.

Design outcomes

Primary

MeasureTime frame
1)Improvement in dry eye symptoms, assessed using the Ocular Surface Disease Index (OSDI) score. 2)Increase in tear secretion, assessed by Schirmer s strip test. Timepoint: 30 days

Secondary

MeasureTime frame
1)Change in visual acuity, assessed using Snellen s chart. 2)Reduction in ocular redness, assessed clinically. 3)Improvement in blurring of vision, assessed using Ocular Surface Disease Index (OSDI) score. Timepoint: 30 days

Countries

India

Contacts

Public ContactDR MOHAMMAD ABBAS RAZA

Luqman Unani Medical College Hospital and Research center

raza.abbas35@gmail.com9717736995

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026